MOSCOW, 15 March – RIA Novosti. Experts at the Paul Ehrlich German Institute for Vaccines and Biomedical Medicines have noted an increase in cases of a rare type of cerebral vein thrombosis after vaccination against COVID-19 with a drug from the British-Swedish company AstraZeneca, the institute said in a statement.
It was on the recommendation of the Paul Ehrlich Institute that Germany on Monday, following a number of other countries, suspended the use of the AstraZeneca vaccine. The head of the German Ministry of Health, Jens Spahn, said that he did not see an alternative to the decision to suspend the use of this vaccine in the country, but expressed the hope that the drug could be used again after additional research.
“Analyzing the new data, experts from the Paul Ehrlich Institute are observing a marked increase in the incidence of a specific form of very rare cerebral vein thrombosis associated with a decrease in platelet count and bleeding coinciding with vaccinations with the AstraZeneca COVID-19 vaccine,” the institute said.
It is noted that new cases of complications were noted as of Monday, March 15, compared with data on March 11.
The institute stressed that the new data is now being studied by specialists from the European Medicines Agency (EMA). People who have already received the AstraZeneca vaccine and whose condition continues to deteriorate four days after vaccination are advised to seek immediate medical attention.
The EMA said last week that it is continuing to investigate incidents of patients vaccinated with a single batch of AstraZeneca vaccine in a number of EU countries and who have later reported thromboembolic complications. The World Health Organization has recommended that countries continue to use the vaccine.
A number of EU countries, including Austria, Estonia, Lithuania, Luxembourg, Latvia, Denmark, Iceland, Bulgaria, and Norway have suspended the use of the AstraZeneca vaccine, which has been approved by the EMA for use in the European Union. On Monday, in particular, the use of the drug was suspended by Italy, France, Germany and Spain.